Pivotal bioVenture Partners Investment Advisor’s Rallybio RLYB Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.7M	Sell	300,579 -2	-0%	-$14	0.96%	11
2025 Q4	$1.65M	Hold	300,581	–	–	0.64%	11
2025 Q3	$1.2M	Hold	300,581	–	–	0.69%	9
2025 Q2	$813K	Hold	300,581	–	–	0.5%	11
2025 Q1	$1.56M	Hold	300,581	–	–	1.27%	8
2024 Q4	$2.31M	Hold	300,581	–	–	1.56%	8
2024 Q3	$2.81M	Hold	300,581	–	–	1.67%	8
2024 Q2	$3.22M	Hold	300,581	–	–	2.48%	6
2024 Q1	$4.45M	Hold	300,581	–	–	2.86%	6
2023 Q4	$5.75M	Hold	300,581	–	–	1.46%	8
2023 Q3	$8.1M	Hold	300,581	–	–	3.23%	5
2023 Q2	$13.6M	Hold	300,581	–	–	4.49%	5
2023 Q1	$13.7M	Hold	300,581	–	–	5.65%	5
2022 Q4	$15.8M	Buy	300,581 +16,667	+6%	+$984K	6.87%	3
2022 Q3	$32.9M	Hold	283,914	–	–	12.01%	2
2022 Q2	$17.1M	Hold	283,914	–	–	8.64%	3
2022 Q1	$15.9M	Hold	283,914	–	–	7.5%	3
2021 Q4	$21.7M	Hold	283,914	–	–	9.06%	3
2021 Q3	$39.9M	Buy	+283,914	New	+$33.3M	14.11%	2

Other funds holding RLYB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's RLYB Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor reduced its Rallybio (RLYB) stake by 0% in Q1 2026, selling an estimated $14 and leaving 300,579 shares worth $2.7M. The position accounts for 0.96% of the portfolio, ranked #11.

Pivotal bioVenture Partners Investment Advisor first reported a position in RLYB in Q3 2021 and has held it in 19 quarters since. The position peaked at $39.9M in Q3 2021. 38 funds tracked by Wall St. Rank hold RLYB as of Q1 2026.

Pivotal bioVenture Partners Investment Advisor held 300,579 shares of Rallybio worth $2.7M as of Q1 2026.
Pivotal bioVenture Partners Investment Advisor sold 2 Rallybio shares in Q1 2026, an estimated $14.
Rallybio made up 0.96% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #11 holding.
Pivotal bioVenture Partners Investment Advisor first reported a position in Rallybio in Q3 2021 and has held it in 19 quarters since.
Pivotal bioVenture Partners Investment Advisor's Rallybio position peaked at $39.9M in Q3 2021.
38 funds tracked by Wall St. Rank held Rallybio as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.